Skip to main content

CONMED Corp

CNMD
Exchange
NYSE
Industry
Electromedical & Electrotherapeutic Apparatus
SEC CIK
0000816956

No open-market purchases or sales by CONMED Corp insiders were filed in the last 90 days; 248 institutions reported holding it in 13F filings for Q2 2026, worth $1.12B in total; no superinvestor holds it.

Key figures

Market capClose on Nov 16, 2026
$1.47B
Insider buysOpen market, last 90 days
0
Insider sellsOpen market, last 90 days
0
13F holdersQ2 2026, +13 vs. previous quarter
248
13F valueReported value at the end of Q2 2026
$1.12B
Superinvestors holdingAt the end of Q2 2026
0

Price chart

From SEC filings, in USD.

Revenue, FY2025
$1.37B
+5.2% year over year
Net income, FY2025
$47.1M
−64.5% year over year
Free cash flow, FY2025
$150.9M
−2.0% year over year
Revenue, Q3 FY2026
$335.6M
−0.7% year over year

Revenue flow, FY2025

Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest
1.86M
Shares sold short
Change
−51.0K
−2.7% vs. previous
Days to cover
4.29
At average daily volume

Superinvestors holding CNMD, Q2 2026

Go to the superinvestors tab

No superinvestor reported holding CNMD at the end of Q2 2026.

Latest insider trades

See all insider trades

Open-market purchases and sales by CONMED Corp insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Nov 24, 2025 (view filing)Nov 213 daysGlaze RichardChief Information OfficerSSale−257$41.21−$10.6K−100.0%0 after10b5-1
Nov 7, 2025 (view filing)Nov 61 dayGarner Todd WExecutive Vice President & CFOSSale−3.50K$43.00−$150.5K−65.6%1.84K after10b5-1
Sep 15, 2025 (view filing)Sep 123 daysFarkas CharlesDirectorSSale−2.00K$53.53−$107.1K−11.9%14.9K after2 lots
Aug 8, 2025 (view filing)Aug 71 dayGarner Todd WExecutive Vice President & CFOSSale−598$52.45−$31.4K−100.0%0 after
May 6, 2025 (view filing)May 51 dayFarkas CharlesDirectorSSale−4.00K$56.94−$227.8K−19.7%16.3K after
Feb 13, 2025 (view filing)Feb 112 daysGlaze RichardChief Information OfficerSSale−257$65.35−$16.8K−100.0%0 after
Jun 17, 2024 (view filing)Jun 143 daysPeters Stanley W IIIPresident AS and AETSSale−4.00K$71.82−$287.3K−98.4%63 after
May 14, 2024 (view filing)May 131 dayBronson David MDirectorPPurchase+1.35K$72.09+$97.3K+8.9%16.5K after
May 10, 2024 (view filing)May 82 daysSchwarzentraub Barbara JDirectorPPurchase+1.44K$69.26+$99.9KNew position1.44K after
May 8, 2024 (view filing)May 62 daysAronson Martha GoldbergDirectorPPurchase+2.00K$70.98+$142.0KNew position2.00K after

Top 10 13F holders, Q2 2026

See all 248 holders

The largest institutional positions in CONMED Corp at the end of Q2 2026; share changes are against Q1 2026.

Institutions holding CNMD in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
BlackRock, Inc.4,820,739$157.8M0.00%−4,434−0.1%Reduced
Earnest Partners LLC2,505,295$82.0M0.30%−64,358−2.5%Reduced
Vanguard Portfolio Management LLC2,188,761$71.6M0.00%+112,344+5.4%Added
Fuller & Thaler Asset Management, Inc.1,579,917$51.7M0.14%−61,849−3.8%Reduced
State Street Corp1,417,468$46.4M0.00%+33,450+2.4%Added
Vanguard Capital Management LLC1,355,728$44.4M0.00%−28,314−2.0%Reduced
Bank of America Corp1,341,409$43.9M0.00%−61,211−4.4%Reduced
Dimensional Fund Advisors LP1,317,370$43.1M0.01%−75,550−5.4%Reduced
SEI Investments Co988,151$32.3M0.03%−16,564−1.6%Reduced
Invenomic Capital Management LP842,162$27.6M1.65%−92,439−9.9%Reduced

Holders of 5% or more of CNMD

See all 3 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of CONMED Corp.

Largest holders of CNMD from 13D and 13G filings
HolderLatest formStakeChangeFirst filedLatest filingFiling
BlackRock, Inc.13G/A15.10%4.68M shares–Jul 18, 20251 filingJul 18, 2025SEC
Vanguard Portfolio Management LLC13G6.87%2.12M sharesNewApr 29, 20261 filingApr 29, 2026SEC
Vanguard Capital Management LLC13G5.25%1.62M sharesNewApr 29, 20261 filingApr 29, 2026SEC